STUDY QUESTION: Does thyroid autoimmunity (TAI) predict live birth rate in euthyroid women after one treatment cycle in IUI patients?
Introduction
For couples facing fertility problems, artificial insemination with homologous or donor semen is a very popular treatment option worldwide. IUI is the first line treatment in couples with unexplained subfertility, cervical factor subfertility and male subfertility. Success rates of IUI are well described (Botchan et al., 2001; Custers et al., 2008; De Brucker et al., 2009) . Data regarding the outcome of fertility treatment in the presence of thyroid autoimmunity (TAI) are conflicting and the optimal upper value of thyroid-stimulating hormone (TSH) in the presence or the absence of TAI remains controversial. The use of ART is particularly suited to evaluate the frequency of miscarriage compared to spontaneous pregnancy. Indeed, in spontaneous pregnancy, miscarriage rate may be underestimated by a significant proportion of unnoticed spontaneous early pregnancy termination. So far, the impact of TAI in female patients on pregnancy outcome after IUI has not been investigated.
Complications after ART have been linked to TAI and non-thyroidrelated auto-immune disease. In the case of IVF-ICSI these potential risks could have been eliminated by the IVF procedure, underestimating the risks of thyroid related autoimmunity.
Since IVF procedures may bypass some of the theoretical action points of any underlying auto-immune process in comparison to IUI we hypothesized that risks related to the impact of TAI on fertility outcome after IUI treatment may be different from those observed in the IVF-ICSI setting.
The present study looks at live birth rate after a first cycle of IUI in a large historical cohort of euthyroid women not being treated for thyroid dysfunction, systematically screened for the presence of TAI and thyroid function at entry between 2010 and 2015. Primary endpoint is the effect of TAI (anti-thyroid peroxidase (TPO)+) on live birth rate. Secondary endpoint is the effect of TSH on live birth rate.
Material and Methods

Patients
After approval of our institutional review board, we retrospectively included all 3143 patients who started their first IUI cycle in our center between 1 January 2010 and 31 December 2014 with follow-up of outcome until 31st December 2015. Patients with thyroid dysfunction were excluded (TSH <0.01 mIU/l; TSH >5 mIU/l). These cut offs were selected since they are the predominately used in previous studies on this topic in the literature. Patients under treatment with levothyroxine or anti-thyroid drugs were excluded. To avoid any inter-laboratory bias, only patients who performed their laboratory screening in our institution were included. Use of donor sperm was not an exclusion criterion. These patients were then divided into two main groups: patients anti-TPO+ and patients anti-TPO− (control group).
Live birth delivery after 25 weeks of gestation was taken as the primary endpoint of our study. As secondary endpoint we investigated the effect of different upper cut-off limits of preconceptional TSH threshold's (<2.5 and <5.0 mIU/l) on live birth delivery in the total cohort.
Miscarriage was defined as every pregnancy which did not result in a delivery. Miscarriage rate per group was defined as miscarriage per pregnancy (Fig. 1) . Furthermore, the influence of thyroid function (TSH, free thyroxine (fT4)), anti-TPO status, age, smoking, BMI, ovarian reserve [anti-mullerian hormone (AMH) and FSH], indication for IUI, cycle stimulation and parity on live birth was analyzed. Ovarian reserve is assessed by measurement of FSH level on Day 3 of the menstrual cycle and by the AMH level.
Based on the online registration system which is mandatory in Belgium and used by all fertility centers pregnancy follow-up was ensured by sending questionnaires to patients and their doctor, or by telephone queries whenever questionnaires were incomplete or in case of missing data.
IUI
Clinical and laboratory procedures
In the present retrospective cohort study, we analyzed the outcome of IUI with the use of either fresh partner sperm or cryopreserved donor semen in 3143 women who started their first treatment cycle. Many of these patients, which mostly had normal menstrual cycles, received mild ovarian hyperstimulation (MOH) with either clomiphene citrate 50-100 mg from Day 3 to Day 7 of the menstrual cycle or human menopausal gonadotrophins-75-150 U from Day 3 of their cycle onwards. Patients were monitored in the follicular phase with the usual hormonal blood tests and ultrasound. If the ultrasound indicated a sufficient number of welldeveloped follicles of at least 17 mm diameter, patients were triggered with an injection of 5000 U hCG (Pregnyl ® , Organon, Oss, the Netherlands) or where monitored until a spontaneous LH rise appeared. Fresh partner sperm or frozen-thawed donor sperm with at least 1 × 10 6 progressively motile spermatozoa using a Frydman catheter (Laboratoires CCD, Paris, France) was used for the IUI procedure. Sperm quality was expressed as total motile sperm count. As luteal support, nearly two-third of the patients were advised to use intravaginal micronized progesterone three times 200 mg (Utrogestan, Besins, Paris France). Pregnancies were diagnosed by a standard serum assay for hCG showing levels of >10 IU/l on at least two successive occasions. Live birth delivery after 25 weeks of gestation was the main outcome measure of our study. All provisions are implemented by the laboratory of hormonology and tumor markers of our institution. Serum TSH, fT4 and TPO-Abs were measured using the Elecsys electrochemiluminescence immunoassays on a Cobas 6000 immunoanalyzer (Roche Diagnostics, Mannheim, Germany). The reference values are 0.27-4.2 mIU/l for TSH, 9.3-17.0 ng/l (12-23.2 pmol/l; 1 ng/l = 1.29 pmol/l) for fT4 and <34 kIU/l for TPO-Abs.
The Elecsys TPO-Ab assay was performed on samples from 870 healthy test subjects in Leipzig Germany, and in 95% of the population, values were below 34 kIU/l. Inclusion and exclusion criteria were used according to the National Academy of Clinical Biochemistry (NACB) guidelines (guideline 33). The inter and intra assay CVs were <2% and <6.5% for TSH, ≤2% and <5% for FT4, <5% and ≤7% for TPO-Abs.
Data analysis
The primary outcome of this retrospective cohort study is delivery resulting in at least one live birth in patients anti-TPO+ compared to patients anti-TPO−. The delivery of more than one child was given the same weight as the delivery of a singleton. We calculated a statistical power of 91% for an expected difference in live birth rate of 9% at the 5% alpha level in this retrospective cohort study.
The analyzed populations (anti-TPO+ and anti-TPO−) were first described according to major participant characteristics. Continuous variables were presented as means and standard deviations and categorical variables as percentages. Comparison between groups is presented as odds ratio (95% CI) for between-group difference. The statistical comparisons for continuous data were assessed with Wilcoxon-Mann-Whitney test. The x 2 test was performed to compare count data. Both groups are further analyzed according to pregnancy outcomes, including pregnancy, miscarriage rate and live birth.
In the multiple logistic regression, live birth delivery was set as the dependent variable, with independent variables being age, TAI status, TSH, fT4, BMI, smoking habits, ovarian reserve (AMH and Day 3 FSH), indication for IUI, cycle stimulation and parity.
Computational procedures are performed using Statistics Package for Social Sciences for Windows version 20 (SPSS Inc., Chicago, IL, USA).
Results
Patient's characteristics
Of the 3143 included patients, 187 had an anti-TPO positive (Group 1) and 2956 an anti-TPO negative status (Group 2 = control group). There was a significant difference in mean age between anti-TPO+ (33.83 ± 4.57 years) and the anti-TPO− (32.34 ± 4.96 years) groups (Table I .) There was neither a significant difference in BMI (23.86 ± 4.67 kg/m 2 vs. 24.10 ± 4.71 kg/m 2 ), nor in smoking habit (3.70% vs. 3.60%). The percentage of women that had delivered in the past was similar in anti-TPO+ women compared to anti-TPO− women (8.60% vs. 11.80%).
Ovarian reserve in terms of Day 3 FSH and AMH was similar in both groups. In the anti-TPO+ group 7.5% patients had an irregular cycle versus 8.0% in the anti-TPO− group. There was no significant difference between both groups (OR 0.92; CI: 95% 0.53; 1.62; P = 0.78). No significant difference was seen in the menstrual cycle length between anti-TPO+ (30.32 ± 10.94) days and anti-TPO− (31.34 ± 13.50) days groups (P = 0.52).
Thyroid function revealed a significantly higher TSH level (2.02 ± 0.96 mIU/l vs. 1.65 ± 0.78 mIU/l) in anti-TPO+ patients and similar fT4 level in both groups. Anti-TPO antibodies values (anti-TPO ab) were significantly higher in anti-TPO+ patients (189.90 ± 158.52 kIU/l vs. 8.41 ± 4.49 kIU/l). No difference was noted in terms of sperm quality (TMC).
Early outcome parameters
There was no significant difference between groups in respect to the use of MOH, the use of trigger medication and the use of luteal support. There was however a significantly higher estradiol level (456.32 ± 338.99 ng/l vs. 402.12 ± 401.59 ng/l) and follicle count (1.43 ± 0.83 vs. 1.30 ± 0.83) in the anti-TPO+ patient group (Table II) .
Overall success rates
Patients with TAI
Twenty two patients (11.80%) out of the 187 patients in the anti-TPO+ group became pregnant. Of these patients 19 (86.4%) delivered and 3 (13.6%) had a miscarriage (Fig. 1) .
Patients without TAI
Three hundred fifty-four patients (12%) out of the 2956 patients in the anti-TPO− group became pregnant. Of these patients 291 (82.2%) delivered and 63 (17.8%) had a miscarriage (Fig. 1) .
First cycle outcome comparison according to anti-tpo status
Between-group comparison did not show any significant differences between the anti-TPO+ and anti-TPO− group with respect to live birth delivery-, pregnancy-or miscarriage rate with odds ratio at 1.04 (95% CI: 0.63; 1.69), 0.98 (95% CI: 0.62; 1.55) and 0.74 (95% CI: 0.23; 2.39), respectively (Table III) .
First cycle outcome comparison according to different TSH thresholds
This retrospective study is able to detect a 10% difference in live birth rate; according to different TSH threshold-levels with a power of 99% and an alpha error of 5%. There were no significant differences in live birth delivery-, pregnancy-or miscarriage rate when comparing subgroups according to TSH level (TSH ≥2.5 mIU/l vs. TSH <2.5 mIU/l) with odds ratio at 1.05 (95% CI: 0.76; 1.47), 1.04 (95% CI: 0.76; 1.41) and 0.95 (95% CI: 0.47; 1.93), respectively (Table IV) .
Multiple logistic regression analysis on the influence of different variables
Multiple logistic regression analysis in the overall group indicated that MOH and the presence of secondary infertility, had a significant effect on delivery rates with a parameter estimate 2.53 (Clomiphene citrate P < 0.001), 1.921 (FSH P = 0.002) and 11.839 (P < 0.001), respectively.
However, no significant difference was seen between anti-TPO+ group and anti-TPO− group in terms of proportions of women that received MOH (OR 0.77; 95% CI: 0.57; 1.04). In addition, there was no significant difference between anti-TPO+ group and anti-TPO− group in terms of proportions of women included for different IUI indications (see Table I Furthermore, multiple logistic regression analysis in the overall group indicated that AMH and smoking, had a significant effect on delivery rates with a parameter estimate of 1.064 (P = 0.0007) and 0.088 (P = 0.016), respectively.
Discussion
To the best of our knowledge, this is the first study to investigate the association between TAI and fertility outcome in euthyroid women in the context of IUI. In the present retrospective cohort study, we found no significant differences in fertility outcomes among euthyroid women, not being treated for thyroid dysfunction, with and without TAI, treated with IUI. Live birth delivery rates were comparable between anti-TPO+ and anti-TPO− euthyroid women. Women with a TSH value between 2.5 and 5 mIU/l before IUI had comparable fertility outcome to women with a TSH value <2.5 mIU/l.
These results may contribute to the discussion of the role of TAI and the use of preconception-specific TSH cut-off values in regard to fertility outcome. Indeed, TAI and TSH have independently been associated with adverse pregnancy outcome after spontaneous conception (Thangaratinam et al., 2011) or after ART. In ART, two meta-analyses (Toulis et al., 2010; Busnelli et al., 2016) found a possible detrimental effect of TAI on the course of pregnancy. In the meta-analysis of four studies, Toulis et al. estimated a 2-fold increase in risk of a miscarriage in subfertile euthyroid woman with TAI compared to women without TAI, although no significant effect of TAI status on the clinical pregnancy-and delivery rate in women undergoing IVF could be noted. In another meta-analysis of 12 studies, Busnelli et al. showed a negative effect of TAI in terms of an increased risk of miscarriage and a decreased chance of live birth. Both meta-analyses quoted a cautious interpretation of the data, because of heterogeneity among studies included, due to small cohort studies, different causes of infertility included and methodological differences of assays, using different cutoff levels for TSH, fT4 and thyroperoxidase antibodies.
The results of the present study are in line with more recent data, analyzing the effect of TAI status and preconception TSH cut-off values on IVF/ICSI outcome data in infertile women. Lukaszuk et al. compared pregnancy outcome between 114 TAI positive and 495 TAI negative infertile women. They found no significant differences in fertilization rate, implantation, pregnancy rates and live birth rates, nor did they confirm a higher risk of miscarriage (Lukazuk et al., 2015) . Also, Sakar et al. showed comparable pregnancy and miscarriage rates between 49 TAI positive and 202 TAI negative women after IVF. Delivery rates were not stated Sakar et al. (2016) . Tan et al. (2014) found that pregnancy outcome after ICSI was comparable among women with and without TAI. These authors selected only infertile couples with a male factor of infertility, concluding that any previous possible association between pregnancy outcome and TAI status might rather be due to a bias related to the inclusion of mainly female causes of infertility.
Whether the cause of pregnancy loss and preterm delivery can be pinned down to the presence of thyroid antibodies in the setting of ART remains unsettled. Several hypotheses have been put forward to account for a possible causal relation between TAI and a negative obstetrical outcome. First, it has been suggested that autoimmunity as such might be accountable. The presence of TAI may be a surrogate for a general immune imbalance, targeting the reproductive tract leading to implantation failure. Others relate thyroid antibodies causally to fertility problems and subsequent pregnancy loss. fluid. These thyroid antibodies may pass the 'follicle-blood' barrier during maturation of a secondary follicle, mediating cytotoxicity and damaging the maturing oocyte, thereby reducing its quality and fertilization potential (Monteleone et al., 2011) . Second, thyroid antibodies may reflect a subtle decrease of thyroid function, with an unfavorable pregnancy outcome. A positive TAI status increases the risk of developing (sub)clinical hypothyroidism (Medici et al., 2012) . Evolution to (sub)clinical hypothyroidism may be more frequent in ART and after ovarian hyperstimulation since the procedure can exert an additional strain on the thyroid. Most studies have correlated preconception TSH values and fertility outcome as in the present study. We do acknowledge the lack of serial measurement of TSH during the IUI procedure.
In today's guidelines of the American Thyroid Association and American Association of Clinical Endocrinologist, preconceptional and first-trimester pregnancy thresholds for the upper limit of TSH to diagnose and treat (sub)clinical hypothyroidism in women attempting pregnancy is generally recommended at >2.5 mIU/l in particular in the presence of TPO antibodies. However, evidence to advocate a cut-off of 2.5 has been graded poor to fair but it is argued that the potential benefits outweigh the potential risks. In the recent guidelines of the American Society for Reproductive Medicine (Subclinical hypothyroidism in the infertile female population: a guideline. Practice Committee of the American Society for Reproductive Medicine, 2015) it is stated that although there is fair evidence that subclinical hypothyroidism defined as a TSH >4 mIU/l during pregnancy is associated with miscarriage, there is insufficient evidence that TSH levels between 2.5 and 4 mIU/l are associated with miscarriage and adverse pregnancy outcomes. Our data add strength to this statement, since we were unable to show adverse effects on fertility outcome between higher and lower category for TSH, within the normal non-pregnant range. These findings are in line with a retrospective cohort study by Karmon et al. (2015) who also evaluated differences in IUI outcomes among euthyroid women with preconception TSH values. In addition, one has to keep in mind the less obvious but potential hazards that may be associated with a possible (over)treatment with levothyroxine. Indeed a recent study by Korevaar et al. (2016) pointed toward the association of maternal thyroid overtreatment during early pregnancy with deleterious effects on offspring IQ and brain morphology in childhood.
In the present study, at baseline both patients groups had similar characteristics. There was a significant higher mean TSH and anti-TPO antibodies (anti-TPO ab) in the anti-TPO+ group at the beginning of fertility treatment. In addition, there was also a significant difference in mean age at baseline. When applying multivariate logistic regression neither anti-TPO status nor TSH values predicted live birth rate. AMH, smoking, secondary infertility, controlled ovarian hyperstimulation but not age, were significant predictors of live birth rate. Smoking has been associated with an increase in implantation failure and a decrease in the odds for a live birth (Penzias, 2012) and women trying to get pregnant are advised to stop smoking and avoid chronic exposure to secondhand smoke. The influence of secondary infertility has recently been described by Atasever et al., 2016 . Also controlled ovarian hyperstimulation is known to increase success rate after IUI (van Rumste et al., 2008) and AMH seems to be a good predictive factor for live birth in IUI (Speyer et al., 2013; Bakas et al., 2015) . Surprisingly, age did not influence the outcome in the present study. However, Ibérico et al. (2004) also found no significant association of age with pregnancy rates. As in our present study, Ibérico only published pregnancy rates per cycle, whereas other authors published cumulative pregnancy rates or pregnancy rates per cycle based on different cycles per couple. Indeed, if we were to look only at the outcome after the first cycle in the study by De Brucker et al., 2009 , delivery rates between age groups would be comparable and differences only become apparent after multiple cycles. However, the debate on the influence of age in IUI is not completely closed due to the lack of level one studies.
In conclusion, this large retrospective cohort study is the first to investigate the association between TAI and fertility outcome in euthyroid women in cases of IUI. In the present study, we failed to find any difference in live birth rates in women with and without anti-TPO antibodies undergoing IUI. Moreover, we were unable to confirm a negative effect of TSH level above 2.5 mIU/l on delivery rate. Advocating levothyroxine treatment at TSH levels between 2.5 and 5 mIU/l needs careful reconsideration since an (over)treatment may have deleterious effects on offspring IQ and brain morphology in childhood. A large prospective study is eagerly awaited to establish once and for all what the optimal cut-off value of TSH should be in the setting of fertility treatment.
The strength of this study is its large cohort size powered for the primary aim, live birth analysis with high follow-up rate. The majority of the baseline characteristics of both groups were similar, thereby excluding confounding by obstetrical history, lifestyle factors, ovarian reserve, IUI indication or sperm quality on the outcome of interest, live birth rate.
The limitations of this study are its retrospective design and the absence of region-specific reference ranges for thyroid hormones and the absence of follow-up of TSH values during IUI and subsequent pregnancy. Moreover, there was a time difference of 5 months between thyroid assessment and the start of stimulation. The area where the study was conducted corresponds to a mild iodine deficient area, which may have influenced thyroid function. Future studies should look at TSH cut-off values in larger prospective cohorts of anti-TPO+ women, treated for infertility.
We conclude that our study indicates that TAI (anti-TPO+) does not independently determine live birth rate in the setting of IUI treatment in euthyroid women not being treated for thyroid dysfunction.
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